跳转到主要内容

Human chorionic gonadotrophin hormone for preventing recurrent miscarriage

Miscarriage is the loss of a pregnancy before 24 weeks of gestation. Recurrent miscarriage (RM) is the loss of three or more consecutive pregnancies, which can cause significant physical and psychological harm with increased depression, anxiety and lowered self-esteem. RM can be linked to systemic maternal disease, such as diabetes mellitus, thyroid disease and polycystic ovary syndrome. In many cases, the cause of RM may remain unknown despite thorough investigations. Current strategies for preventing RM include the administration of hormones involved in maintaining pregnancy, one of which is human chorionic gonadotrophin (hCG). This hormone is important for the continued production of progesterone from the corpus luteum and may have a role in the implantation of the embryo.

This review included five randomised controlled studies, involving 596 women. When comparing the women who were treated with hCG versus placebo or no treatment, we found a benefit in using hCG. However, when two of the older studies with weaker methodology were excluded, there was no longer evidence of benefit in using hCG for preventing RM. As a result, we were unable to make firm recommendations. There were no documented adverse effects associated with using hCG. More good quality studies with larger sample sizes are needed in order to evaluate the use of hCG compared with other treatments and non-pharmacological strategies, such as early and accessible carer contact and support.

研究背景

Recurrent miscarriage (RM) is defined as the loss of three or more consecutive pregnancies. Further research is required to understand the causes of RM, which remain unknown for many couples. Human chorionic gonadotrophin (hCG) is vital for maintaining the corpus luteum, but may have additional roles during implantation which support its use as a therapeutic agent for RM.

研究目的

To determine the efficacy of hCG in preventing further miscarriage in women with a history of unexplained RM.

检索策略

We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 September 2012) and reference lists of retrieved studies.

纳入排除标准

Randomised controlled trials investigating the efficacy of hCG versus placebo or no treatment in preventing RM. Quasi-randomised trials are included. Cluster-randomised trials and trials with a cross-over design are excluded.

资料收集与分析

Two review authors independently assessed trials for inclusion and assessed the methodological quality of each study. Date were extracted by two review authors and checked for accuracy.

主要结果

We included five studies (involving 596 women). Meta-analysis suggested a statistically significant reduction in miscarriage rate using hCG.The number of women needed to treat to prevent subsequent pregnancy loss was seven. However, when two studies of weaker methodological quality were removed, there was no longer a statistically significant benefit (risk ratio 0.74; 95% confidence interval 0.44 to 1.23). There were no documented adverse effects of using hCG.

作者结论

The evidence supporting hCG supplementation to prevent RM remains equivocal. A well-designed randomised controlled trial of adequate power and methodological quality is required to determine whether hCG is beneficial in RM.

引用文献
Morley LC, Simpson N, Tang T. Human chorionic gonadotrophin (hCG) for preventing miscarriage. Cochrane Database of Systematic Reviews 2022, Issue 3. Art. No.: CD008611. DOI: 10.1002/14651858.CD008611.pub2.

我们的Cookie使用

我们使用必要的cookie来使我们的网站工作。我们还希望设置可选的分析cookie,以帮助我们进行改进。除非您启用它们,否则我们不会设置可选的cookie。使用此工具将在您的设备上设置一个cookie来记住您的偏好。您随时可以随时通过单击每个页面页脚中的“Cookies设置”链接来更改您的Cookie首选项。
有关我们使用cookie的更多详细信息,请参阅我们的Cookies页面

接受全部
配置